Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI

Davide Cao, Matthew A. Levin, Samantha Sartori, Bimmer Claessen, Anastasios Roumeliotis, Zhongjie Zhang, Johny Nicolas, Rishi Chandiramani, Rashi Bedekar, Zaha Waseem, Ridhima Goel, Mauro Chiarito, Bonnie Lupo, Jeffrey Jhang, George D. Dangas, Usman Baber, Deepak L. Bhatt, Samin K. Sharma, Annapoorna S. Kini, Roxana Mehran

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Perioperative cardiovascular complications are important causes of morbidity and mortality associated with non-cardiac surgery, especially in patients with recent percutaneous coronary intervention (PCI). We aimed to illustrate the types and timing of different surgeries occurring after PCI, and to evaluate the risk of thrombotic and bleeding events according to the perioperative antiplatelet management. Patients undergoing urgent or elective non-cardiac surgery within 1 year of PCI at a tertiary-care center between 2011 and 2018 were included. The primary outcome was major adverse cardiac events (MACE; composite of death, myocardial infarction, or stent thrombosis) at 30 days. Perioperative bleeding was defined as ≥ 2 units of blood transfusion. A total of 1092 surgeries corresponding to 747 patients were classified by surgical risk (low: 50.9%, intermediate: 38.4%, high: 10.7%) and priority (elective: 88.5%, urgent/emergent: 11.5%). High-risk and urgent/emergent surgeries tended to occur earlier post-PCI compared to low-risk and elective ones, and were associated with an increased risk of both MACE and bleeding. Preoperative interruption of antiplatelet therapy (of any kind) occurred in 44.6% of all NCS and was more likely for procedures occurring later post-PCI and at intermediate risk. There was no significant association between interruption of antiplatelet therapy and adverse cardiac events. Among patients undergoing NCS within 1 year of PCI, perioperative ischemic and bleeding events primarily depend on the estimated surgical risk and urgency of the procedure, which are increased early after PCI. Preoperative antiplatelet interruption was not associated with an increased risk of cardiac events.

Original languageEnglish
Pages (from-to)380-389
Number of pages10
JournalJournal of Thrombosis and Thrombolysis
Issue number2
StatePublished - Feb 2022


  • Ahrombosis
  • Antiplatelet therapy
  • Bleeding
  • Non-cardiac surgery
  • PCI


Dive into the research topics of 'Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI'. Together they form a unique fingerprint.

Cite this